Introduction to Therapies Used to Treat SMA

Clinical Brief: Historical and Current Treatment Paradigms for SMA

Main Discussion Topics

• Evolution of SMA care from supportive/palliative to disease-modifying approaches
• Description of current FDA-approved disease-modifying therapies
• Mechanisms of action for available SMA treatments
• Challenges in accurately measuring treatment response

Key Points for Physicians

• Before disease-modifying therapies, SMA care focused on respiratory support, nutrition, orthopedic management, and pain control.
• Current treatment options include nusinersen (intrathecal antisense oligonucleotide), risdiplam (oral splicing modifier), and onasemnogene abeparvovec (gene therapy, limited to children younger than 2 years).
• Nusinersen and risdiplam enhance SMN protein production from the SMN2 gene.
• Standardized assessment tools have limitations at both ends of the functional spectrum.

Notable Insights

Implementation of consensus care guidelines and multidisciplinary care improved survival outcomes even before disease-modifying therapies were available, highlighting the importance of comprehensive care approaches.

Clinical Significance

The treatment paradigm for SMA has evolved from palliative care to a multifaceted approach combining disease-modifying therapies with supportive care, requiring ongoing adaptation of assessment methods to capture meaningful clinical outcomes.